Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
GLP-1 Medication Titration: When to Increase and When to Stay at Your Current Dose Lori Fauquier, APN-C, WHNP Feb 6, 2025 3 min read Updated: Jun 7, 2025 GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have revolutionized medical weight loss, helping individuals control cravings, regulate blood sugar, and achieve sustainable weight loss
Final sale items cannot be returned or replaced
It is available as effervescent tablets
IshibashiYMatsuiTOjimaANishinoYNakashimaSMaedaSet al
Another approach is to skip dose levels for individuals who achieve adequate weight loss and metabolic improvement at lower doses
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
US$ 22.58
US$ 25.85
US$ 27.46
